| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7158 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08 |
| filingDate |
1997-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2002-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2002503950-A |
| titleOfInvention |
Eosinophil eotaxin receptor |
| abstract |
(57) [Summary]nThe eosinophil eotaxin receptor was isolated, cloned and sequenced. This receptor is a human β-chemokine receptor and was named “CC CKR3”. Using the eosinophil eotaxin receptor, a compound that binds to the eosinophil eotaxin receptor can be screened and identified. Such compounds would be useful in the treatment and prevention of atopic diseases including allergic rhinitis, dermatitis, conjunctivitis, and especially bronchial asthma. |
| priorityDate |
1996-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |